Vista Pharmaceuticals (524711) Q3 2026 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and nine months ended December 31, 2025, along with the limited review report.

• Financial statements prepared in accordance with Indian Accounting Standards (Ind AS).

Financial highlights

• Revenue from operations for Q3 FY26 was ₹241.82 lakhs, down from ₹255.50 lakhs in Q3 FY25.

• Net loss for Q3 FY26 stood at ₹231.94 lakhs, compared to a net loss of ₹132.23 lakhs in Q3 FY25.

• Loss before tax for Q3 FY26 was ₹328.04 lakhs, higher than the ₹180.44 lakhs loss in Q3 FY25.

• For the nine months ended December 31, 2025, total income was ₹568.17 lakhs, with a net loss of ₹619.83 lakhs.

• Basic and diluted EPS for Q3 FY26 was (₹0.41), and for the nine months was (₹1.05) per share.

Outlook and guidance

• Management intends to clear outstanding statutory dues in subsequent periods.